Genetics of biliary tract cancers and emerging targeted therapies.

Abstract

Biliary tract cancers (BTC), which encompass intra- and extrahepatic cholangiocarcinomas and gallbladder carcinomas, are a genetically diverse collection of cancers. Evidence suggests distinct models of molecular and pathologic progression, and a growing body of genetics data points to a heterogeneous collection of underlying mutations in key oncogenes and tumor suppressor genes. Although tumor genetics have been used to tailor individual treatment regimens and guide clinical decision making in other cancers, these principles have not been applied in BTC. Recent clinical trials with targeted therapies seem promising, although the relationships between subsets of patients with positive responses to therapy and tumor genetics remain unexplored. Here, we summarize the molecular pathogenesis and genetics of BTCs and animal modeling and relate these to recent and ongoing clinical trials with targeted agents.

DOI: 10.1200/JCO.2009.27.4787
010020020102011201220132014201520162017
Citations per Year

656 Citations

Semantic Scholar estimates that this publication has 656 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Hezel2010GeneticsOB, title={Genetics of biliary tract cancers and emerging targeted therapies.}, author={Aram F. Hezel and Vikram Deshpande and Andrew X. Zhu}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2010}, volume={28 21}, pages={3531-40} }